Li-Cor Biosciences

Li-Cor Biosciences of Lincoln, Neb., and Spectros Corp. of Portola Valley, Calif., have announced a nonexclusive licensing and supply agreement to couple the former company’s IRDye 800CW to the latter’s targeted biomarkers. Additionally, the companies have agreed to develop targeted fluorescent contrast agents for real-time imaging and treatment of prostate and ovarian cancer.





LATEST NEWS

• Exail Signs LLNL Contract, Partners with Eelume
  Apr 26, 2024
• Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
  Apr 26, 2024
• Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
  Apr 25, 2024
• DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
  Apr 25, 2024
• Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
  Apr 24, 2024
• One-Step Hologram Generation Speeds 3D Display Creation
  Apr 24, 2024
• Innovation Award Winners for Laser Technology Honored in Aachen
  Apr 23, 2024
• Intech 2024: AI Arrives on the Shop Floor
  Apr 22, 2024